Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
BETHESDA, Md., March 23, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq:GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress.
Related news for (GANX)
- Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
- 24/7 Market News Snapshot 06 October, 2025 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)
- MoBot alert highlights: NASDAQ: RUN, NASDAQ: CASI, NYSE: UP, NASDAQ: IOBT, NASDAQ: GANX (08/15/25 02:00 PM)
- Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
- Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
